Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung H-P, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, et al.